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AbstrACt
Introduction Opioid agonist treatment is effective for opioid 
dependence and newer extended- release buprenorphine 
(BUP- XR) injections represent a significant development. 
The Community Long- Acting Buprenorphine (CoLAB) study 
aims to evaluate client outcomes among people with opioid 
dependence receiving 48 weeks of BUP- XR treatment, 
and examines the implementation of BUP- XR in diverse 
community healthcare settings in Australia.
Methods and analysis The CoLAB study is a prospective 
single- arm, multicentre, open- label trial of monthly BUP- XR 
injections in people with opioid dependence. Participants are 
being recruited from a network of general practitioner and 
specialist drug treatment services located in the states of 
New South Wales, Victoria and South Australia in Australia. 
Following a minimum 7 days on 8–32 mg of sublingual 
buprenorphine (±naloxone), participants will receive 
monthly subcutaneous BUP- XR injections administered by a 
healthcare practitioner at intervals of 28 days (−2/+14 days). 
The primary endpoint is participant retention in treatment 
at 48 weeks after treatment initiation. Secondary endpoints 
will evaluate dosing schedule variations, craving, withdrawal, 
substance use, health and well- being, and client- reported 
treatment experience. Qualitative and costing substudies will 
examine implementation barriers and facilitators at the client 
and provider level.
Ethics and dissemination The study has received ethics 
approval from the St Vincent’s Hospital Sydney Human 
Research Ethics Committee (Ref. HREC/18/SVH/221). 
The findings will be disseminated via publication in peer- 
reviewed journals, presentations at national and international 
scientific conferences, and in relevant community 
organisation publications and forums.
trial registration number NCT03809143
Protocol identifier CoLAB1801, V.4.0 dated 01 August 
2019
IntroduCtIon
The two main medications used in opioid 
agonist treatment (OAT), methadone and 
buprenorphine (buprenorphine;±nal-
oxone), are well established as safe and effec-
tive treatments for opioid dependence.1 2 
OAT reduces illicit opioid use, crime, over-
dose, mortality risk and risk of HIV and hepa-
titis C virus (HCV) acquisition.3–5 Despite 
these clear benefits, OAT carries some risks, 
including adverse events, injection of medica-
tion intended for oral/sublingual administra-
tion, diversion and overdose.6–8
In response to these risks, supervised daily 
dosing at a specialist clinic or pharmacy 
is a feature of OAT in many countries1–4 at 
least during the early stages of treatment. 
strengths and limitations of this study
 ► This is an open- label trial with broad eligibility cri-
teria and flexible extended- release buprenorphine 
(BUP- XR) dosing to more accurately reflect ‘real- 
world’ clinical practice compared with previous ran-
domised controlled trials.
 ► The study will be conducted at a range of health-
care settings, including specialist opioid treatment 
services and general practice, publicly and private-
ly operated facilities, in metropolitan and regional 
locations.
 ► The sample size for the clinical intervention cohort 
is relatively small with no comparison group; how-
ever, rich and detailed participant interview data will 
be collected to evaluate the impact of BUP- XR on 
people who are opioid dependent, including those 
participants who discontinue treatment early.
 ► This mixed- method protocol (clinical intervention 
cohort, qualitative research and costing) will focus 
on the barriers and facilitators to implementation, 
and will be used to inform models of care, clini-
cal guidelines and training programmes for health 
providers.
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Attendance for daily dosing is burdensome for both 
clients and service providers. People in treatment often 
state that attendance for supervised dosing is restric-
tive on many aspects of daily life5 especially if signifi-
cant travel time, cost and inconvenience is involved in 
attending during limited clinic dosing hours. Addition-
ally in Australia, people receiving OAT frequently pay the 
costs of pharmacy dispensing fees6 which is a significant 
burden for many clients, and also a barrier to treatment 
access for many who are on income support payments 
or disability support pensions.6 In some Australian juris-
dictions, publicly funded specialist treatment services 
cover the costs of supervised dosing so there is no cost to 
the client, but this requires substantial staffing resources 
that may be alternatively utilised for case manage-
ment or providing health- related and/or psychosocial 
interventions.
Recently developed extended- release buprenorphine 
(BUP- XR) injections represent a significant develop-
ment in OAT. They are administered subcutaneously 
by a healthcare provider, releasing buprenorphine at a 
controlled rate over the dosing interval. Currently formu-
lations enable weekly9 10 or monthly administration.9–11 
Early studies indicate that they provide rapid onset and 
sustained release of buprenorphine,7 8 12 blockade at the 
mu- opioid receptors minimising the euphorigenic opioid 
effects of illicit opioid use,13 14 sustained reductions in 
illicit opioid use and good treatment retention.15 16 Once- 
monthly BUP- XR injections have been approved in the 
USA, Canada, Australia17 and Europe, and once- weekly 
BUP- XR injections have been approved in Australia18 19 
and Europe.20
BUP- XR injections are expected to be associated with 
several potential benefits. Eliminating the need to attend 
for frequent dosing should increase convenience to 
clients, and may reduce the costs to clients and providers. 
Monthly BUP- XR injections may enhance treatment effi-
cacy as a result of fewer missed doses, more consistent 
buprenorphine plasma levels and improved treatment 
exposure.21 BUP- XR injections delivered by a health-
care professional may also reduce the diversion and use 
via unintended routes of administration observed with 
sublingual buprenorphine treatment.22–24
There is also substantial client interest in BUP- XR. 
A recent survey of people who used opioids regularly25 
found that two- thirds of respondents believed BUP- XR 
was a good treatment option for them. Interest was high 
among those currently in OAT as well as those who were 
not, with no differences according to prior methadone 
vs buprenorphine experience.25 The most common 
advantages endorsed by participants were less frequent 
service attendance, ‘more time to do other things’ and 
freedom to travel for work or holidays.25 Despite these 
potential advantages, it is important to understand how 
BUP- XR impacts on client outcomes and whether the 
outcomes observed with BUP- XR are similar to sublingual 
buprenorphine despite less frequent contact with treat-
ment services.
Six- month retention on two BUP- XR formulations were 
63% and 69%, respectively,15 16 in phase III clinical trials. 
These retention levels are substantially higher than those 
observed in routine treatment with sublingual buprenor-
phine,26 however, the extent to which these trials reflect 
‘real- world’ clinical practice is limited. The double- 
blind placebo- controlled or active- controlled designs of 
these trials required all participants to attend clinics on 
a weekly basis, which does not reflect the likely routine 
practice with injections of monthly BUP- XR. Clients were 
a highly selected group, with a range of exclusions. There 
are limited data available on the adherence, retention 
and safety (adverse events) of BUP- XR injections over the 
longer term, especially the potential for local injection 
site complications. One open- label safety study with flex-
ible dosing with either weekly or monthly BUP- XR over 48 
weeks found high levels of retention (73.6% at 48 weeks) 
and the treatment was well tolerated with a safety profile 
consistent with that for sublingual buprenorphine.27 
Additional studies conducted over such extended period 
of treatment and adverse event monitoring are needed.
Implementing BUP- XR in the diverse range of treat-
ment settings in Australia and many other countries also 
presents challenges. Although specialist publicly funded 
clinics with onsite pharmacies are available in some juris-
dictions, the treatment models in other jurisdictions rely 
predominantly on primary care prescribers and commu-
nity pharmacies. Implementing BUP- XR in these diverse 
settings has important service- level and system- level impli-
cations, including the development of new models of care 
and new procedures for drug storage and administration.
The overarching aims of the Community Long- Acting 
Buprenorphine (CoLAB) studies detailed in this protocol 
are:
1. To evaluate the participant outcomes following the 
implementation of a monthly injection of BUP- XR for 
the treatment of opioid dependence in community- 
based treatment settings with a focus on retention in 
treatment, opioid and other illicit drug use, adherence 
with the administration schedule and participants’ ex-
periences of the implementation.
2. To develop and document the implementation of 
a monthly injection of BUP- XR for the treatment of 
opioid dependence with an emphasis on the feasibility 
and practical clinical, regulatory and supply issues in 
settings representative of Australian clinical practice.
MEthods And AnAlysIs
study design
The CoLAB study is a prospective single- arm, multi-
centre, open- label trial of monthly BUP- XR (Sublocade) 
in people with opioid dependence, with qualitative and 
costing substudies. The primary objective is to examine 
treatment retention at 48 weeks following initiation 
of BUP- XR injections in clients with opioid depen-
dence transferred from a stable dose of sublingual 
buprenorphine.
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Table 1 Participant inclusion and exclusion criteria for the CoLAB study
Inclusion criteria Exclusion criteria
 ► Aged 18–65 years
 ► Opioid- dependent currently receiving 
treatment
 ► Has been receiving 8–32 mg sublingual 
buprenorphine±naloxone tablets/film for at 
least 7 days
 ► Negative pregnancy test at screening and 
baseline in females of childbearing potential
 ► Currently lactating or pregnant, or of childbearing potential and not willing 
to avoid becoming pregnant during the study
 ► History or presence of allergic or adverse response (including rash or 
anaphylaxis) to buprenorphine or the ATRIGEL Delivery System.
 ► Significant, medical or psychiatric conditions which would compromise 
compliance with the protocol and/or client safety. Specific conditions of 
interest include hepatic disease (Child- Pugh Class B or C), severe renal 
or respiratory disease, or severe cognitive impairment or psychiatric 
condition that impairs the ability to provide informed consent.
 ► Subjects who are currently participating in any other clinical study 
involving investigational medication(s).
 ► Inability or unwillingness to provide informed consent or abide by the 
requirements of the study.
CoLAB, Community studies of Long- Acting Buprenorphine.
A total of 100 people with opioid dependence will 
be enrolled from seven Australian study site locations, 
which include a mix of service providers in community 
settings (eg, primary care based general practitioners) 
and in specialist clinic settings. Sites were selected to be 
representative of the range of treatment service models 
typical in Australia, to facilitate efficient capture of imple-
mentation issues. All site principal investigators (PIs) 
are current OAT prescribers, either addiction specialists 
(n=6) or general practitioners with experience in deliv-
ering OAT (n=1), and were provided additional training 
by the study team on BUP- XR administration and manage-
ment. Participant recruitment commenced in May 2019 
and is expected to reach completion in late 2019. Quali-
tative and costing substudies will also be conducted and 
are described here in brief. The CoLAB study protocol 
addresses all criteria in the 2013 Standard Protocol Items: 
Recommendations for Interventional Trials guidelines 
(online supplementary appendix 1, and study findings 
will be reported in accordance with these criteria.
Participant eligibility
The study population is individuals with opioid depen-
dence who are receiving 8–32 mg sublingual buprenor-
phine treatment (for at least 7 days), express interest in 
receiving BUP- XR, and are deemed suitable for treat-
ment with BUP- XR by the site investigator. Eligibility 
criteria are deliberately broad to allow enrolment of a 
diverse group of participants. Anyone with significant, 
medical or psychiatric conditions which would compro-
mise compliance and/or client safety will be excluded. 
Specific conditions of interest include hepatic disease 
(Child- Pugh Class B or C), severe renal or respiratory 
disease, or severe cognitive impairment or psychiatric 
condition that impairs the ability to provide informed 
consent (eg, psychosis, delirium, hypomania, severe 
depression or suicidal ideation). While potential drug–
drug interactions for BUP- XR are similar to sublingual 
buprenorphine, any participant with a history or presence 
of allergic or adverse response to the ATRIGEL Delivery 
System gel polymer component of Sublocade BUP- XR 
will be excluded. Full eligibility criteria are described in 
table 1.
study schedule
The study consists of a screening phase (up to 4 weeks); 
treatment intervention phase (48 weeks) and follow- up 
at 4 weeks after the last dose of study medication, as 
depicted in the study schema (figure 1):
(A) Screening: Following informed consent (please 
refer to online supplementary file 1), screening assess-
ments include: physical assessment, medical history, 
substance use and related treatment history, urine preg-
nancy test, urine drug screening, concomitant medica-
tion, and eligibility confirmation. (B) Treatment: BUP- XR 
treatment will be provided over 44 weeks, involving study 
visits every 4 weeks. Each study visit consists: (1) clinical 
and safety assessments (2) Administration of BUP- XR 
injection and (3) research interviews via telephone. (C) 
Post- treatment follow- up: 4 weeks after the last dose of 
BUP- XR, for collection of safety event and research inter-
view data.
The procedures conducted at each visit throughout the 
study are detailed in the CoLAB schedule of assessments 
(table 2).
buP-Xr treatment
The protocol allows for participants to receive injections 
of Sublocade scheduled 28 days apart (−2/+14 days; 
figure 1). Sublocade contains a buprenorphine base in 
a precipitation delivery system (ATRIGEL) of biodegrad-
able polylactide- co- glycolide polymer and biocompatible 
solvent (N- methyl- pyrrolidone), which, in contact with 
aqueous interstitial fluid, solidifies in the subcutaneous 
space to form a depot. This solid depot provides sustained 
release of buprenorphine over a minimum of 28 days 
through diffusion and polymer degradation.28 29
Participants will follow a dosing schedule aligned with 
the Australian Sublocade product information.11 This 
involves two Sublocade doses of 300 mg at baseline and 
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Figure 1 CoLAB study schema. CoLAB, Community studies 
of Long- Acting Buprenorphine; GP, general practitioner; BUP- 
XR, extended- release buprenorphine.
week 4, reflecting ‘loading’ doses that elevate plasma 
buprenorphine levels. Thereafter (doses 3–12), doses 
are flexible with either 100 or 300 mg every 4 weeks, as 
decided by the site investigator in consultation with the 
participant (figure 1). Relevant factors in dose consider-
ation include client craving and withdrawal, client rating 
of dose adequacy, opioid and other substance use, and 
adverse events. In general, doses should be maintained 
(on 100 mg or 300 mg) if no clinically significant opioid 
withdrawal, cravings, or dose- related adverse events are 
identified, and the patient is satisfied with his/her current 
dose. Doses should generally be reduced from 300 mg to 
100mg if the patient reports dose- related adverse events 
(eg, sedation, lethargy, headaches, nausea), the patient 
is seeking to ultimately withdraw from OAT, or the 
patient reports the dose is ‘too high’. Doses should be 
increased from 100 mg to 300 mg if the patient is not 
achieving treatment goals (eg, persistent unsanctioned 
opioid use, withdrawal symptoms or cravings), no dose- 
related adverse events to buprenorphine are identified, 
or the patient reports the dose is inadequate and there 
are no significant clinical safety concerns. All injections 
will be administered by a medical practitioner or nurse 
trained to perform the task. The product is administered 
by subcutaneous injection into the abdominal area only, 
with the injection site rotated each dose to avoid potential 
irritation.
Supplemental doses of up to 8 mg daily sublingual 
buprenorphine for 14 days are permitted, however, after 
the first 2 BUP- XR doses additional doses will require 
approval by the study chief medical officer, who is avail-
able to provide clinical advice to site staff throughout 
the study. Treatment is to be discontinued in the event 
of pregnancy, non- adherence to dosing regimen (more 
than 56 days between injections), participant removal of 
the depot or medical deterioration in clinical condition 
of the participant according to the site PI. Where BUP- XR 
treatment is discontinued for any reason, individualised 
advice is provided by the study chief medical officer, typi-
cally to reintroduce sublingual buprenorphine based on 
first principles.
Participant interviews
Participants will complete interviews via telephone at inter-
vals of 28 days (±4 days) throughout the treatment period. 
After the first BUP- XR dose, the interview schedule is 
independent of the dosing schedule and participants who 
discontinue treatment will remain in follow- up for inter-
views. The interviews are structured from a combination 
of validated tools and additional questions developed by 
the protocol steering committee (PSC), collecting client- 
reported withdrawal, craving, substance use, overdose, 
health service utilisation, work attendance, pain, quality 
of life, and treatment satisfaction data. The question-
naires included in the interviews are described in table 2. 
Participants are reimbursed AUD50 per completed inter-
view as compensation for their time.
outcome measures and analysis
The primary objective of the CoLAB trial is to examine 
treatment retention at 48 weeks following initiation of 
BUP- XR injections at intervals of 28 days (−2/+14 days) in 
clients with opioid dependence transferred from a stable 
dose of sublingual buprenorphine. Secondary objectives 
include evaluation of dosing schedule variations, craving, 
withdrawal, substance use, health and well- being, and 
client- reported treatment experience over the treatment 
period. Study endpoints are described in table 3.
safety event reporting
In addition to standard adverse event and serious 
adverse event (SAE) data collection and reporting to 
the ethics committee, regulatory authority and Indivior 
pharmacovigilance, information on adverse events of 
special interest (AESI) will be collected. AESI include: 
pregnancy, buprenorphine overdose, severe hepatic 
impairment, depot removal and severe precipitated 
withdrawal. A medical monitor independent of UNSW, 
the CoLAB study and Indivior will review all SAEs for 
relatedness to BUP- XR and/or study participation. A 
data safety monitoring board will review interim safety 
data once the first 20 participants have reached month 6 
of the study, with subsequent review commensurate with 
its risk assessment.
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Table 2 CoLAB study schedule of assessments
Study week
Screening Treatment Post- Tx
−4 to 0 0 4 8 12 16 20 24 28 32 36 40 44 48
Clinical assessments     
Medical history and physical examination X   
Substance use and treatment history X   
Australian Treatment Outcome Profile (ATOP) X   
Past 7 days sublingual buprenorphine dose   X   
Eligibility confirmation*   X   
Pregnancy test and contraception 
counselling†
X X X X X X X X X X X X X X
Urine drug screening‡ X X X X X X X X X X X X X X
Concomitant medication review X X X X X X X X X X X X X X
Adverse events   X X X X X X X X X X X X X
Dose adequacy   X X X X X X X X X X X X X
Clinical Opiate Withdrawal Scale   X X X When participant reports BUP- XR dose inadequacy or withdrawal, 
only
BUP- XR treatment     
300 mg BUP- XR injection   X X   
100 or 300 mg BUP- XR injection§       X X X X X X X X X X   
Telephone interviews     
Demographics   X   
Subjective Opiate Withdrawal Scale   X X X X X
Opioid Craving Scale   X X X X X X X X X X X X X
Dose Adequacy   X X X X X X X X   
ATOP   X X X X X X X X X X X X X
Overdose (self- report)   X X X X X X X X X X X X X
Health service utilisation   X X X X X
Australian Quality of Life four- dimension   X X X X X
Pain, Enjoyment, General Activity scale   X X X X X
Patient Health Questionnaire   X X X X X
WHO Absenteeism and Presenteeism   X X X X X
Treatment Satisfaction Questionnaire for 
Medication
  X X X X X
Treatment Perceptions Questionnaire   X X X X X
End of Treatment Questionnaire   X
Early Cessation Questionnaire     When participant has discontinued BUP- XR treatment early, 
for any reason
    
*Includes routine clinical tests where needed to confirm eligibility, forexample, suspected severe hepatic or renal impairment.
†In women of childbearing potential.
‡At 3 selected sites, for validation of participant- reported drug use during interviews.
§From the 3rd BUP- XR injection, the dose prescribed can be either 100 or 300 mg, at the discretion of the treating Investigator.
BUP- XR, extended- release buprenorphine; CoLAB, Community studies of Long- Acting Buprenorphine.
sample size
Existing clients of participating general practice and public 
specialist drug and alcohol services will be approached 
and following informed consent will be screened for 
enrolment. A total of 100 participants will be enrolled 
and receive at least one dose of BUP- XR. The sample will 
allow estimation of the retention primary endpoint with 
adequate precision, and evaluation of factors impacting 
implementation at a variety of site types (specialist and 
primary care; public and private). Estimates of retention 
are based on phase III trials with BUP- XR products (esti-
mated retention: 69%16; 95% CI 60.0% to 77.9%).
data management
Clinical data will be collected by participating sites and 
entered into a web- based electronic case report form, 
OpenClinica, an open- source clinical trial software for 
electronic data capture and clinical data management. 
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Table 3 Primary and secondary endpoints of the CoLAB study
Primary objective Primary endpoint
1. To examine extended- release buprenorphine BUP- XR) 
treatment retention at 48 weeks
1.1 Proportion of participants retained in treatment at 48 weeks 
following initiation of monthly depot buprenorphine injections. 
Treatment retention is defined as remaining on active depot 
buprenorphine medication at 48 weeks.
Secondary objective Secondary endpoint
1. To examine BUP- XR treatment retention and 
engagement in ongoing clinical care at 48 weeks
1.1 Proportion of participants retained in treatment at 48 weeks 
following initiation of monthly depot buprenorphine injections and 
engaged in ongoing clinical care. Treatment retention is defined 
as remaining on active depot buprenorphine medication AND 
completing a clinical assessment at 48 weeks.
2. To evaluate opioid craving, withdrawal, opioid and other 
drug use
2.1 Change in clinically assessed (urinary drug screen) and client- 
reported use of opioids
2.2 Change in clinically assessed (urinary drug screen) and client- 
reported use of other drugs
2.3 Change in clinically assessed opioid craving
3. To evaluate client utilisation of buprenorphine 
medication during the study, including BUP- XR dose 
variation, adherence with dosing schedule and dose 
supplementation
3.1 Percentage of participants who completed 12 injections (per 
protocol) during the 48 week study period.
3.2 Percentage of participants requiring dose adjustments with 
sublingual buprenorphine/buprenorphine- naloxone (and dose) 
during treatment
3.3 Percentage of participants maintained on 300 mg per month 
and 100 mg per month after the initial 2×300 mg injection
3.4 Mean duration of continuous treatment (weeks)
3.5 Reasons for drop- out among non- completers
3.6 Percentage of participants presenting to receive treatment 
within 7 and 14 days of the next scheduled injection
3.7 Mean duration (days) between administered injections
4. To evaluate treatment safety and tolerability by 
monitoring adverse events, and events of clinical interest 
such as drug–drug interactions and pain management in 
clients treated with BUP- XR
4.1 Percentage of participants with different types of ‘special 
events of interest’
4.2 Percentage of participants with common adverse events 
(reported in greater than 5%)
4.3 Percentage of participants with at least one severe or 
potentially life threatening (grade 3 or 4) adverse event;
4.4 Percentage of participants withdrawn from treatment due to 
unacceptable adverse events
5. To describe client- reported changes to health and social 
well- being
5.1. Health service utilisation during treatment and estimated 
costs (including client travel)
5.2. Hours worked in paid employment/study
5.3. Other changes in health and social well- being (as measured 
by PEG, AQol- 4D, ATOP client surveys)
6. To evaluate demographic, drug use and treatment 
factors associated with treatment outcomes
6.1 Demographic, drug use and treatment characteristics 
associated with treatment outcomes, for example, participant 
retention
7. To evaluate client- reported experience of treatment 7.1 Client- reported treatment satisfaction measures
8. To examine BUP- XR treatment retention at 24 weeks 8.1 Percentage of participants retained in treatment at 24 weeks 
following initiation of monthly depot buprenorphine injections. 
Treatment retention is defined as remaining on active depot 
buprenorphine medication at 24 weeks.
9. To document the cost of the treatment at different 
settings
9.1 Using process measures identify the resource use at both 
client and facility level
AQoL- 4D, Australian Quality of Life four- dimension; ATOP, Australian Treatment Outcome Profile; CoLAB, Community studies of Long- Acting 
Buprenorphine; PEG, Pain, Enjoyment, General Activity.
On- site monitoring and source data verification will be 
completed at regular intervals by the sponsor for data 
quality assurance and to ensure compliance with the 
study protocol, International Conference on Harmonisa-
tion Good Clinical Practice (ICH- GCP) guidelines, ethics 
approvals and sponsor standard operating procedures. 
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Interviews will be conducted via telephone by UNSW 
researchers, not involved in the participants’ clinical care 
or study team located at the site. Data will be entered 
by interviewers into the OpenClinica database. Multiple 
contact methods (eg, mobile, email, social media 
accounts) and those for participants’ family or friends will 
be collected at baseline to facilitate intensive follow- up 
and maximise retention in research interviews.
Qualitative research substudy
The qualitative substudy aims to examine factors impacting 
BUP- XR implementation from the client, service provider, 
clinician and policy- maker perspective. Clients and 
providers will be interviewed to explore clients’ interests, 
expectations and experiences of receiving BUP- XR treat-
ment, providers’ experiences of administering BUP- XR 
treatment in their service, and the organisational impli-
cations of implementing BUP- XR in service settings with 
varied characteristics in terms of model of care, staffing 
and policy. Qualitative interview data will be generated to 
examine factors that clients, service providers, clinicians 
and policy- makers perceive as important in the imple-
mentation and delivery of BUP- XR for the treatment of 
opioid dependence in community- based general practice 
and specialist treatment settings; how this new treatment is 
translated and made to work in its implementation contexts 
and practices; how the introduction of this treatment may 
impact treatment experience and shape service provi-
sion; and the possibilities of, and challenges posed by, this 
new treatment. Purposive sampling will be used to recruit 
consenting participants to participate in semistructured 
interviews, conducted either in person (where possible) or 
via telephone. Clients will be sampled to maximise diver-
sity in gender, previous treatment experience and duration 
on BUP- XR, including those who discontinue treatment 
early. Interviews will capture a range of treatment time-
points including early BUP- XR experience soon after the 
first dose, and follow- up interviews after at least 6 months 
of treatment.
Costing substudy
A costing substudy will be undertaken to evaluate the 
impact of BUP- XR treatment on both participating 
services and participants. Resource use will be identified 
at both the client and facility level and will include process 
measures obtained through participant records (eg, medi-
cation charts), facility records (eg, appointment records) 
and interviews with individual clinical team members (eg, 
site PI, other treating staff and pharmacist)to document 
procedures related to drug storage, drug administration 
and client care. A bottom- up or activity- based costing 
will be used, where each of the resources used will be 
identified, measured and valued. This will include (but 
is not limited to) the implementation or start- up costs; 
staff training; treatment costs including time to prescribe, 
order/transport medication, dispense and administer; 
monitor drug storage (eg, refrigeration, temperature 
incursions and wastage); cost of the medication; any 
counselling or other healthcare costs, and any other 
consumables/supplies. Costs will be obtained from state- 
based salary and wage schedules, the Medicare Benefits 
Scheme (diagnostics, consultations etc), and other stan-
dard unit costs where relevant. Any relevant overhead 
and on- costs will be included. Monthly participant inter-
views will include collection of travel costs for BUP- XR 
treatment, changes in work hours, and health service util-
isation unrelated to the facility providing BUP- XR.
Patient and public involvement
Design of the CoLAB implementation study was informed 
by a survey (n=402) evaluating patients’ priorities and 
concerns regarding BUP- XR.25 The research question, 
study design, participant information sheet and survey 
tools were reviewed by a community reference panel 
which included individuals with a history of or current 
drug use. Findings of the study will be disseminated 
through a lay language summary posted to participants, 
as well as publications distributed by advocacy agencies 
representing people who use drugs.
dIsCussIon
BUP- XR injections have been established as efficacious 
in licensing randomised controlled trials,15 16 however, 
further data are limited.27 The CoLAB study will provide 
data that reflect the ‘real world’ patient reported 
outcome and experience measures in a context as close 
to routine clinical care as possible, while also providing 
important data on costs, client and provider perspectives, 
and implementation facilitators and barriers. These data 
will further inform models of care, clinical guidelines and 
training programmes for health providers.
Although a recent survey conducted in Australia found 
that the majority of people who use opioids regularly 
anticipated that BUP- XR would be a good treatment 
option for them,25 criteria for effective BUP- XR client 
selection have not been established. One concern is 
that reduced clinician contact may impact treatment 
outcomes for some clients, through loss of daily structure 
and engagement with support services. Qualitative studies 
of potential clients found that ‘longer’ BUP- XR formula-
tions (eg, monthly or 6 monthly) were viewed as benefi-
cial for clients who wanted to avoid thinking about drugs 
and their networks of people who use drugs, wanted to 
reduce stigma, and desired ‘normality’ and ‘recovery’.30 
‘Shorter’ BUP- XR formulations (eg, weekly) were viewed 
as beneficial to clients who were new to OAT, worried 
about the safety and reliability/effectiveness of OAT, 
want a ‘break’ from illicit opioids, and those who need 
more regular contact with services to monitor/support 
them.30 It is important to note, however, that the interest 
in a hypothetical treatment may not translate into actual 
experience and uptake of monthly BUP- XR injections.
Reduced frequency of clinic attendance also has impli-
cations for services providing OAT. While it may poten-
tially free up resources for providing other services, the 
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impact on clients’ other healthcare needs during BUP- XR 
treatment is unknown. OAT for opioid dependence in 
Australia is incorporated into a broader treatment model 
of care involving regular clinical reviews, case manage-
ment and psychosocial interventions, with services indi-
vidualised for each client.1 In the CoLAB study, the 
minimum frequency of scheduled clinical reviews with a 
site investigator (or delegated clinician) is every 42 days. 
Participation in psychosocial services (eg, counselling) is 
encouraged, but not mandated, in the study protocol to 
more accurately reflect ‘real world’ clinical practice. The 
CoLAB study will provide important data on how clients 
receiving monthly BUP- XR injections use psychosocial 
and healthcare interventions in the periods between 
injections.
The study will also explore implementation issues related 
to management and administration of the BUP- XR medi-
cation. Sublocade must be stored and managed consis-
tent with jurisdictional requirements for Schedule 8 (an 
Australian classification of drugs of dependence that are 
subject to additional regulatory controls regarding their 
manufacture, supply, distribution, possession and use31). 
Sublocade must also be stored under refrigerated condi-
tions (2°C–8°C) and is supplied via cold chain to partici-
pating clinics, however, is stable at ambient temperature 
for up to 7 days. The process of BUP- XR management, 
including distribution, receipt, storage and tempera-
ture control, permits and accountability in accordance 
with schedule 8 requirements will be documented to 
identify barriers. Sites with and without onsite schedule 
8 compliant refrigerated storage have been included to 
examine these issues.
Although the study schedule of dosing and assessments 
is designed to allow flexibility and mimic ‘real- world’ clin-
ical scenarios, there are many that will not be evaluated 
within the context of this research protocol. For example, 
all participants must be stable on a daily dose of 8–32 mg 
sublingual buprenorphine for at least 7 days immedi-
ately prior to the first BUP- XR injection. The study will, 
therefore, not provide answers to clinical questions such 
as initiation of Sublocade in patients using methadone 
or illicit heroin, treatment of clients on low sublingual 
buprenorphine doses (less than 8 mg daily) with BUP- 
XR, and transfer of clients between the two current 
BUP- XR products (Sublocade and Buvidal). Clinical 
guidelines regarding these specific scenarios have been 
developed in Australia,31 with recommendations based 
on the available evidence and expert consensus, though 
further research is required. A further limitation is the 
single arm design. The relatively small sample size and 
lack of comparator limits the ability to evaluate effective-
ness and cost- effectiveness of BUP- XR compared with the 
sublingual buprenorphine standard of care; however, the 
CoLAB study will provide important information on the 
client retention, tolerability and acceptability of BUP- 
XR, as well as the cost and key considerations involved 
in integrating this formulation into clinical practice in 
Australia.
The introduction of depot buprenorphine formula-
tions is likely to have significant benefits for some clients 
and their service providers. BUP- XR may not suit all OAT 
clients, and some will prefer methadone or sublingual 
buprenorphine treatment. Current treatment guidelines 
recommend that medication choice is guided by client 
factors such as prior experience with medications, adverse 
events, drug–drug interactions, overdose risks and in some 
cases logistic factors such as travel requirements. It is also 
possible that prescribers may prefer BUP- XR where there 
are concerns regarding a client’s non- medical use (eg, 
injecting, hoarding, diversion to others) of sublingual 
buprenorphine, or a client has a number of risk factors for 
unsupervised dosing that are difficult to mitigate, such as 
homelessness, high- risk substance use, or history of medi-
cation diversion. Uptake and experience of clients will also 
be impacted by the way in which the medication is incor-
porated into existing OAT policies (eg,31), education on 
delivering BUP- XR for healthcare professionals, commu-
nication strategies and engagement of consumer groups 
and peers. The CoLAB study will provide important data to 
inform these activities.
EthICs And dIssEMInAtIon
The study is sponsored and managed by the National Drug 
and Alcohol Research Centre (NDARC), UNSW Sydney, 
Australia. Oversight is provided by a PSC composed of clin-
ical specialists in addiction medicine, epidemiologists with 
expertise in opioid dependence and drug user research, 
qualitative researchers, health economist, NDARC research 
and clinical trials operational staff and representatives 
from participating clinic sites. The protocol was informed 
by a survey of over 400 consumers evaluating attitudes and 
preferences for OAT. The PSC includes representatives 
of community organisations advocating for people who 
use drugs. This study has received ethics approval from 
the St Vincent’s Hospital Sydney Human Research Ethics 
Committee (Ref. HREC/18/SVH/221), and site specific 
assessments have been approved by the local research 
governance offices of participating sites. Future amend-
ments will be similarly submitted for approval. The study 
will be conducted in accordance with ICH- GCP guidelines, 
the Declaration of Helsinki, and all applicable local ethical 
and regulatory requirements. All participants must provide 
written informed consent. The findings will be dissemi-
nated via publication in a peer- reviewed journal and rele-
vant scientific conference presentations. In addition to the 
primary clinical study report, we aim to publish a series of 
secondary papers describing the various components of 
the study, including implementation issues, qualitative and 
costing substudies, and clinical guidance development. The 
authors will disseminate findings to the affected community 
by engaging organisations representing users.
Author affiliations
1National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South 
Wales, Australia
9Larance B, et al. BMJ Open 2020;10:e034389. doi:10.1136/bmjopen-2019-034389
Open access
2School of Psychology, University of Wollongong, Sydney, New South Wales, 
Australia
3Illawarra Health and Medical Research Institute, University of Wollongong, 
Wollongong, New South Wales, Australia
4The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia
5Discipline of Addiction Medicine, University of Sydney, Surry Hills, New South 
Wales, Australia
6The Langton Centre, South East Sydney Local Health District, Surry Hills, New 
South Wales, Australia
7Monash Addiction Research Centre and Eastern Health Clinical School, Monash 
University Peninsula Campus, Frankston, Victoria, Australia
8School of Population and Global Health, University of Melbourne, Melbourne, 
Victoria, Australia
9Centre for Social Research in Health, UNSW Sydney, Sydney, New South Wales, 
Australia
10Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South 
Australia, Australia
twitter Suzanne Nielsen @drsuzinielsen and Jason Grebely @jasongrebely
Acknowledgements Study medication is provided by Indivior. The authors would 
also like to thank all the participants in the study, the study staff, clinical staff, and 
staff in alcohol and other drug services for supporting this research.
Collaborators The CoLAB Study Team are Michael Farrell (Chief Investigator; 
PSC), Louisa Degenhardt (PSC), Nicholas Lintzeris (Chief Medical Officer; PSC), 
Briony Larance (PSC), Suzanne Nielsen (PSC), Jason Grebely (PSC), Gregory Dore 
(PSC), Robert Ali (PSC), Kari Lancaster (PSC), Marian Shanahan (PSC), Carla Treloar 
(PSC), Marianne Byrne (Clinical Trials Manager; PSC), Jeyran Shahbazi (Trial 
Coordinator; PSC), Stella Nalukwago (health economic analyses), Craig Rodgers 
(Site Investigator; PSC), Adrian Dunlop (Site Investigator; PSC), Michael McDonough 
(Site Investigator), Jon Cook (Site Investigator), Mark Montebello (Site Investigator), 
Michael Aufgang (Site Investigator) and Robert Weiss (Site Investigator), Madeline 
News (interview data collection), Zoe Griffin (research data collection).
Contributors BL, SN, MS, LD, KL, JG, GD, RA and MF conceived the original study 
concept, contributed to the study design and obtained funding. BL, NL, MB, JS, SN, 
MS, LD, JG and MF participated in survey development, design of data collection 
and contributed to the detailed trial protocol. MB and BL drafted the manuscript 
with input from all authors. All authors meet the International Committee of Medical 
Journal Editors criteria for authorship and have read and approved the final 
manuscript.
Funding This study is sponsored by the National Drug and Alcohol Research 
Centre, University of New South Wales, Sydney Australia. The Study is supported 
by an Externally Sponsored Collaborative Research grant from Indivior. Indivior 
contributed to the study design and analysis plan. Indivior is supplying its BUP- XR 
product, Sublocade, for all study participants.
disclaimer Indivior will have no role in collection, analysis and interpretation of 
data; in the writing of the manuscript; or in the decision to submit the manuscript 
for publication.
Competing interests Many of the investigators have received investigator- 
initiated, untied educational grants for opioid- related studies from: Indivior (Briony 
Larance, Louisa Degenhardt, Nicholas Lintzeris, Michael Farrell, Suzanne Neilsen); 
Reckitt Benckiser (Briony Larance, Louisa Degenhardt, Nicholas Lintzeris, Michael 
Farrell, Suzanne Nielsen, Robert Ali, Adrian Dunlop); Mundipharma (Briony Larance, 
Louisa Degenhardt, Nicholas Lintzeris, Michael Farrell); and Seqirus (Briony 
Larance, Louisa Degenhardt, Michael Farrell, Suzanne Nielsen).
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
orCId ids
Marianne Byrne http:// orcid. org/ 0000- 0002- 3489- 2532
Suzanne Nielsen http:// orcid. org/ 0000- 0001- 5341- 1055
Louisa Degenhardt http:// orcid. org/ 0000- 0002- 8513- 2218
Marian Shanahan http:// orcid. org/ 0000- 0001- 9873- 3576
rEFErEnCEs
 1 Gowing L, Ali R, Dunlop A, et al. National guidelines for medication- 
assisted treatment of opioid dependence. Canberra: Commonwealth 
of Australia, 2014.
 2 Rhodes T. The becoming of methadone in Kenya: how an 
intervention's implementation constitutes recovery potential. Soc Sci 
Med 2018;201:71–9.
 3 Vuong T, Shanahan M, Nguyen N, et al. Cost- Effectiveness of Center- 
Based compulsory rehabilitation compared to community- based 
voluntary methadone maintenance treatment in HAI Phong City, 
Vietnam. Drug Alcohol Depend 2016;168:147–55.
 4 Independent Expert Working Group. Clinical guidelines on drug 
misuse and dependence update 2017. drug misuse and dependence: 
UK guidelines on clinical management. London: Department of 
Health, 2017.
 5 Madden ALT, Bath N, Winstock AR. Satisfaction guaranteed? what 
clients on methadone and buprenorphine think about their treatment. 
2008;27:671–8.
 6 Rowe J. A raw deal? impact on the health of consumers relative to 
the cost of pharmacotherapy. Melbourne: RMIT University, Centre for 
Applied Social Research, 2007.
 7 Albayaty M, Linden M, Olsson H, et al. Pharmacokinetic evaluation 
of once- weekly and Once- Monthly buprenorphine subcutaneous 
injection depots (CAM2038) versus intravenous and sublingual 
buprenorphine in healthy volunteers under naltrexone blockade: an 
open- label phase 1 study. Adv Ther 2017;34:560–75.
 8 Haasen C, Linden M, Tiberg F. Pharmacokinetics and 
pharmacodynamics of a buprenorphine subcutaneous depot 
formulation (CAM2038) for once- weekly dosing in patients with 
opioid use disorder. J Subst Abuse Treat 2017;78:22–9.
 9 Camurus Pty Ltd. Australian product information. Buvidal Weekly and 
Buivdal monthly (buprenorphine) 2018.
 10 Lintzeris N, Dunlop A, Masters D. Clinical guidelines for use of depot 
buprenorphine (Buvidal® and Sublocade) in the treatment of opioid 
dependence. Sydney, Australia: NSW Ministry of Health, 2019.
 11 Indivior Inc. Australian product information. Sublocade 2019.
 12 Laffont CM, Gomeni R, Heidbreder C, et al. Population 
pharmacokinetic modeling after repeated administrations of RBP-
6000, a new, subcutaneously injectable, long- acting, sustained- 
release formulation of buprenorphine, for the treatment of opioid use 
disorder. J Clin Pharmacol 2016;56:806–15.
 13 Nasser AF, Greenwald MK, Vince B, et al. Sustained- Release 
buprenorphine (RBP-6000) blocks the effects of opioid challenge 
with hydromorphone in subjects with opioid use disorder. J Clin 
Psychopharmacol 2016;36:18–26.
 14 Walsh SL, Comer SD, Lofwall MR, et al. Effect of buprenorphine 
Weekly depot (cam2038) and hydromorphone blockade in individuals 
with opioid use disorder: a randomized clinical trial. JAMA Psychiatry 
2017;74:894–902.
 15 Haight BR, Learned SM, Laffont CM, et al. Efficacy and safety of a 
monthly buprenorphine depot injection for opioid use disorder: a 
multicentre, randomised, double- blind, placebo- controlled, phase 3 
trial. Lancet 2019;393:778–90.
 16 Lofwall MR, Walsh SL, Nunes EV, et al. Weekly and monthly 
subcutaneous buprenorphine depot formulations vs daily sublingual 
buprenorphine with naloxone for treatment of opioid use disorder: 
a randomized clinical TrialEfficacy of subcutaneous Weekly and 
monthly vs daily sublingual dosing of buprenorphine for opioid use 
disorder. JAMA Internal Medicine 2018;178:764–73.
 17 US Food and Drug Administration. Drug approval package: 
SUBLOCADE (buprenoprhine), 2017. Available: https://
www. accessdata. fda. gov/ drugsatfda_ docs/ nda/ 2017/ 
209819Orig1s000TOC. cfm [Accessed 15 Aug 2019].
 18 Sublocade buprenorphine. Therapeutic goods administration. 
public ARTG summary, 2019. Available: http:// tga- search. clients. 
funnelback. com/ s/ search. html? query= sublocade& collection= tga- 
artg& profile= record [Accessed 15 Aug 2019].
 19 Therapeutic Goods Administration. Public ARTG summary: Buvidal 
buprenorphine, 2019. Available: http:// tga- search. clients. funnelback. 
com/ s/ search. html? query= buvidal& collection= tga- artg& profile= 
record [Accessed 15 Aug 2019].
 20 European Medicines Agency. Buvidal marketing Authorisation details, 
2018. Available: https://www. ema. europa. eu/ en/ medicines/ human/ 
EPAR/ buvidal# authorisation- details- section [Accessed 15 Aug 2019].
 21 Rosenthal RN, Goradia VV. Advances in the delivery of 
buprenorphine for opioid dependence. Drug Des Devel Ther 
2017;11:2493–505.
10 Larance B, et al. BMJ Open 2020;10:e034389. doi:10.1136/bmjopen-2019-034389
Open access 
 22 Larance B, Degenhardt L, Lintzeris N, et al. Post- Marketing 
surveillance of buprenorphine- naloxone in Australia: diversion, 
injection and adherence with supervised dosing. Drug Alcohol 
Depend 2011;118:265–73.
 23 Larance B, Lintzeris N, Ali R, et al. The diversion and injection of 
a buprenorphine- naloxone soluble film formulation. Drug Alcohol 
Depend 2014;136:21–7.
 24 Lofwall MR, Walsh SL. A review of buprenorphine diversion and 
misuse: the current evidence base and experiences from around the 
world. J Addict Med 2014;8:315–26.
 25 Larance B, Degenhardt L, Grebely J, et al. Perceptions of extended- 
release buprenorphine injections for opioid use disorder among 
people who regularly use opioids in Australia. Addiction 2019. 
doi:10.1111/add.14941. [Epub ahead of print: 20 Dec 2019].
 26 Burns L, Gisev N, Larney S, et al. A longitudinal comparison 
of retention in buprenorphine and methadone treatment for 
opioid dependence in New South Wales, Australia. Addiction 
2015;110:646–55.
 27 Frost M, Bailey GL, Lintzeris N, et al. Long- Term safety of a Weekly 
and monthly subcutaneous buprenorphine depot (CAM2038) in the 
treatment of adult out- patients with opioid use disorder. Addiction 
2019;114:1416–26.
 28 Indivior Inc. Investigator's brochure. RBP-6000 (buprenorphine in the 
ATRIGEL delivery system. Richmond, USA: Indivior, 2017.
 29 Indivior Inc. Investigator's brochure. buprenorphine (extended- 
release injection) for subcutaneous use. North Chesterfield, USA: 
Indivior, 2018.
 30 Neale J, Tompkins CNE, Strang J. Prolonged- release opioid agonist 
therapy: qualitative study exploring patients' views of 1- week, 
1- month, and 6- month buprenorphine formulations. Harm Reduct J 
2019;16:25.
 31 Therapeutic Goods Administration. Standard for the uniform 
scheduling of medicines and poisons (SUSMP). Australian 
Government Department of Health and Ageing, 2013.
